| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10007745 | HBV | ENSG00000144891.19 | protein_coding | AGTR1 | No | No | 185 | A0A0A0MSE3 D3DNG8 P30556 Q53YY0 Q6NUP5 |
| TVIS10041838 | HBV | ENSG00000144891.19 | protein_coding | AGTR1 | No | No | 185 | A0A0A0MSE3 D3DNG8 P30556 Q53YY0 Q6NUP5 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | AGTR1 |
|---|---|
| DrugBank ID | DB00177 |
| Drug Name | Valsartan |
| Target ID | BE0000062 |
| UniProt ID | P30556 |
| Regulation Type | antagonist |
| PubMed IDs | 11752352; 15579516; 8242249; 12460705; 8577935; 12023686; 32648158 |
| Citations | Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Azizi M, Menard J, Bissery A, Guyenne TT, Bura-Riviere A, Vaidyanathan S, Camisasca RP: Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol. 2004 Dec;15(12):3126-33.@@Criscione L, de Gasparo M, Buhlmayer P, Whitebread S, Ramjoue HP, Wood J: Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol. 1993 Oct;110(2):761-71.@@Shargorodsky M, Leibovitz E, Lubimov L, Gavish D, Zimlichman R: Prolonged treatment with the AT1 receptor blocker, valsartan, increases small and large artery compliance in uncomplicated essential hypertension. Am J Hypertens. 2002 Dec;15(12):1087-91.@@de Gasparo M, Whitebread S: Binding of valsartan to mammalian angiotensin AT1 receptors. Regul Pept. 1995 Nov 10;59(3):303-11.@@Siragy HM, El-Kersh MA, De Gasparo M, Webb RL, Carey RM: Differences in AT2 -receptor stimulation between AT1 -receptor blockers valsartan and losartan quantified by renal interstitial fluid cGMP. J Hypertens. 2002 Jun;20(6):1157-63.@@Ulutas Z, Ermis N, Ozhan O, Parlakpinar H, Vardi N, Ates B, Colak C: The Protective Effects of Compound 21 and Valsartan in Isoproterenol-Induced Myocardial Injury in Rats. Cardiovasc Toxicol. 2021 Jan;21(1):17-28. doi: 10.1007/s12012-020-09590-6. Epub 2020 Jul 9. |
| Groups | Approved; Investigational |
| Direct Classification | Valine and derivatives |
| SMILES | CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O |
| Pathways | Valsartan Action Pathway |
| PharmGKB | PA451848 |
| ChEMBL | CHEMBL1069 |
